Home
About Us
In this Issue
Previous Issue
Editorial Board
How to Contribute
Advertise with Us
Editorial Calendar
Subcribe Now
Global Healthcare Releases provided by Business Wire

 The Publication & Databases on Biotechnology in the Asia Pacific
 
 More free   feature articles 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

EYE ON CHINA
SIMM explores a novel cationic core-shell lipo-nanoparticles for ocular gene drug delivery
Ocular diseases are usually treated with a topical application of drug solutions (i.e. eye drops). These traditional dosage forms account for nearly 90% of currently available marketed formulations. However, ocular physiological barriers and the poor water solubility of drug candidates present a number of problems for the development of ocular drug delivery systems.

Recently, various ophthalmic drug delivery strategies aim at improving the bioavailability of poor soluble ocular drugs have emerged. Among them, lipid-based nanocarriers exhibit a variety of potential advantages as delivery systems for ocular administration. New technological advances and unmet clinical needs provide a key driving force for the research and development of lipid-based nanocarriers for ocular drug delivery.

A novel ocular gene drug delivery system by utilizing cationic core-shell liponanoparticles (DLCS-NP) has been published on Biomaterials. Researchers led by Dr. Gan Yong from the Shanghai Institute of Materia Medica designed the DLCS-NP by hydration of thin lipid film with chitosan nanoparticle (CS-NP) suspension, followed by post-insertion of the cationic phospholipid DOTAP (1,2-dioleoyl-3- trimethylammonium-propane). This specific delivery strategy has multiple functions, including better DNA protecting effect, good cellular uptake efficiency, utilization of multiple endocytic pathways, and endolysosome escaping ability.

The study was supported by the Natural Sciences Foundation of Shanghai China and the National Natural Sciences Foundation of China, and partially supported by National Science & Technology’s Major Project — “Key New Drug Creation and Manufacturing Program”, and the National Basic Research Program of China.

Click here for the complete issue.


About Us | How to Contribute | How to Advertise With Us | Contact Us |

"The views expressed here does not necessarily reflect the views of Asia Pacific Biotech News or its staff."
Copyright © 2014 World Scientific Publishing Co. All rights reserved.